#	Pagina
attuale pagina	/open-h2020/projects/225143/index.html
-1	/open-h2020/projects/211987/index.html
-2	/open-h2020/projects/220742/index.html
-3	/open-h2020/projects/196485/index.html

Opendata, web and dolomites

SLAM-Dx SIGNED

Diagnostic drug response-profiling using SLAMseq

Total Cost €

EC-Contrib. €

Partnership

Views

SLAM-Dx project word cloud

Explore the words cloud of the SLAM-Dx project. It provides you a very rough idea of what is the project "SLAM-Dx" about.

tools erc preparation action overcome predicting precision unprecedented limitation function vivo protocol drug utility greatest 336860 expression limited secondary format severe sequencing cell direct rna therapy day successful deciphering rapid disease systematic time chromatin right stg therapeutics distinction perturbations hampers commercial qualify revolutionize first input dx metabolic microarrays tumor co techniques 96 probe linked seq lack slam preclinical implications precluding sh guiding tool profiling efficacy poc quantification unbiased library proof gene scalable optimization cells candidate slamseq leukemia medicine economy select translational diagnostic primary variety thiol clinical mrna probing treatment alkylation personalised resolution one clinic transcriptional selectivity survival patient decisions

Project "SLAM-Dx" data sheet

The following table provides information about the project.

Coordinator	FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH Organization address address: CAMPUS-VIENNA-BIOCENTER 1 city: WIEN postcode: 1030 website: www.imp.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Austria [AT]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2019-PoC
Funding Scheme	ERC-POC-LS
Starting year	2019
Duration (year-month-day)	from 2019-10-01 to 2021-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH Organization address address: CAMPUS-VIENNA-BIOCENTER 1 city: WIEN postcode: 1030 website: www.imp.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	coordinator	150˙000.00

Map

Project objective

One of the greatest challenges today is to select the right drug for the right patient at the right time. A lack of diagnostic tools for predicting therapy response currently hampers patient-tailored treatment decisions in the clinic with severe implications for economy and – most importantly – patient survival.

Profiling transcriptional responses to drug treatment is a key method for probing the activity of targeted therapeutics and guiding their use in the clinic. A major limitation of established gene expression profiling techniques (such as microarrays and RNA-seq) is their limited time resolution precluding the distinction of direct from secondary transcriptional responses to drug therapy. This hampers their utility for deciphering drug action and guiding patient-tailored treatment decisions.

To overcome this problem, as part of an ERC-StG project (Systematic in-vivo analysis of chromatin-associated targets in leukemia, 336860) I have co-developed thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAMseq) as a rapid, robust and highly scalable method for the unbiased quantification of changes in mRNA production upon cell perturbations. Its unique features (low input cell numbers, short treatment-to-sample time, 1-day protocol library preparation in 96-well format) may qualify SLAMseq as the first method to probe the function, efficacy and selectivity of candidate therapeutics in primary (tumor) cells with unprecedented precision and on a large scale.

In this ERC-PoC project, I propose to establish technical and commercial proof-of-concept for SLAMseq’s application in preclinical and clinical drug development and optimization, and for patient-tailored treatment selection. Upon the successful proof-of-concept for SLAMseq’s application as diagnostic tool, SLAM-Dx has the potential to revolutionize translational research and personalised medicine in a variety of disease areas.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SLAM-DX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SLAM-DX" are provided by the European Opendata Portal: CORDIS opendata.